

Panacea Biotec
Innovation in support of life

November 16, 2018

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Reg.: Compliance under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,


In continuation to our letter dated November 14, 2018 for approving the Un-Audited Financial Results (Provisional) for the quarter and half year ended September 30, 2018 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper copies of Extract of Statement of Un-Audited Financial Results for the quarter and half year ended September 30, 2018, published in the following newspapers on November 15, 2018:-

- Business Standard (English);
- Desh Sewak (Punjabi)

This is for your kind information and record please.

Thanking you,

Yours truly,
for **Panacea Biotec Ltd.**


Vinod Goel
Group CFO and Head Legal
& Company Secretary



Encl.: As above

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

National Centre for Radio Astrophysics
TATA INSTITUTE OF FUNDAMENTAL RESEARCH
NCRA-TIFR, Post Bag 3, Ganeshkhind, Pune University Campus, Pune - 411007

TENDER NOTICE NO. 6 / 2018-2019,
Public Tender No. : NCRA:177:PUB375:2018

Sealed bids are invited in two parts (Part - I Techno commercial Bid & Part-II Price Bid) for supply of Power Line RFI/EMC Filters. Downloading of Tender Document: From November 15, 2018.
For details please visit website: <http://www.ncra.tifr.ref.in/ncra1/public-tenders-1>
OR <http://eprocure.gov.in/epublish/app>

SILICON VALLEY INFOTECH LIMITED
Place: Kolkata
Date: 13th November, 2018
Managing Director, DIN NO. 00174235

CMS FINVEST LIMITED
Regd Office : 10, Princep Street, 2nd Floor, Kolkata - 700072
I : info@cmsinfotech.com, website : www.cmsinfotech.com,
Phone No. - 033-40022880, Fax - 91-33-22379053
CIN : L67120WB1991PLC052782

Statement of Standalone Unaudited Financial Results for the quarter/half year ended 30th September, 2018 (Rs. In Lacs)

Sl. No.	Particulars	Quarter ended 30.09.2018 (Unaudited)	Year to date figures for current period ended 30.09.2018 (Unaudited)	Corresponding 3 months ended in the previous year 30.09.2017 (Unaudited)
1	Total Income from Operations	5.00	7.40	8.92
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	11.01	20.45	13.44
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	11.01	20.45	13.44
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	11.01	20.45	13.44
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	11.01	20.45	13.44
6	Equity Share Capital	1,399.59	1,399.59	1,399.59
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year			
8	Earnings Per Share (of Rs. ___/- each) (for continuing and discontinued operations) -			
9	1. Basic :	0.08	0.15	0.10
10	2. Diluted :	0.08	0.15	0.10

Note: a) The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the Stock exchanges website i.e. www.bseindia.com & www.cse-india.com and on the Company website: www.cmsinfotech.com. b) The impact on net profit / loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a note. c) # - Exceptional and/or Extraordinary Items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

By order of the Board
For CMS FINVEST LIMITED
Sd/- Surendra Kumar Jain, Director
Place: Kolkata
Date: 13th November, 2018
DIN NO. 00166852

CAUTION NOTICE

It is to inform subscribers that signals of some or all of the channels (namely, Cartoon Network, Pogo, WB, HBO and CNN International) are likely to be disconnected after three weeks following Multi System Operator on the ground detailed hereinafter:

Name of MSO(s)/ Cable Operator(s)	Grounds of Disconnection	Areas Which Will Be Affected
Charbhujia Cable Network	(a) non-payment of dues, (b) failure to furnish subscriber reports, (c) failure to allow us to conduct audit of your Digital Addressable	Subscribers catered by DPO across

Avonmore Capital & Management Services Limited

CIN: L67190DL1991PLC045857
Regd. Off.: F-33/3, Okhla Industrial Area, Phase-II, New Delhi - 110020
Tel.: 011-26385056, Fax.: 011-43500787
Website: www.avonmorecapital.in, E-mail ID: secretarial@almondz.com

Extract of Consolidated Unaudited Financial Results for Quarter & Half Year Ended 30 September 2018
Amount in Rs. Lacs

Particulars	Quarter ended			Half year ended		Year ended
	30 September 2018 Unaudited	30 June 2018 Unaudited	30 September 2017 Unaudited	30 September 2018 Unaudited	30 September 2017 Unaudited	31 March 2018 Audited
Total income from operations	2,071	2,173	3,625	4,244	5,230	10,333

Panacea Biotech
Innovation in support of life

Extract of Standalone Financial Results (Unaudited) for the Quarter and Half year ended September 30, 2018
(Rs. in Lakh except per share)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	September 30, 2018 Unaudited	June 30, 2018 Unaudited	September 30, 2017 Unaudited	September 30, 2018 Unaudited	September 30, 2017 Unaudited	March 31, 2018 Audited
Total income from operations	11,858	9,511	15,257	21,369	26,021	57,993
Net Profit / (Loss) for the period (before tax, exceptional and/or extraordinary item)	(4,733)	(5,483)	(221)	(10,216)	(4,853)	(6,124)
Net Profit / (Loss) for the period before tax (after exceptional and/or extraordinary item)	(9,483)	(3,417)	(221)	(12,900)	(4,853)	(6,124)
Net Profit / (Loss) for the period after tax (after exceptional and/or extraordinary item)	(9,749)	(3,683)	(563)	(13,432)	(5,362)	(7,188)
Total comprehensive income for the period (comprising of profit/(loss) for the period (after tax) and other comprehensive income (after tax))	(9,785)	(3,718)	(563)	(13,503)	(5,362)	(7,330)
Equity Share Capital (face value of Re.1 per share)	613	613	613	613	613	613
Earning per Share (of Re. 1 each (annualised, other than Quarter)						
Basic :	(15.92)	(6.01)	(0.92)	(21.93)	(8.75)	(11.74)
Diluted :	(15.92)	(6.01)	(0.92)	(21.93)	(8.75)	(11.74)

Notes: 1. The above is an extract of the detailed format of Quarterly and Half Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly Financial Results is available on the Stock Exchanges websites, NSE-<http://www.nseindia.com>, BSE- <http://www.bseindia.com> and is also available on the Company's website, <http://www.panaceabiotech.com>. 2. The above financial results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their meetings held on November 13, 2018 and November 14, 2018 respectively. Further, the limited review of Financial Results for the Quarter and Half Year ended September 30, 2018, in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, has been carried out by the statutory auditors. 3. The financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ("IND-AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the Companies Act, 2013. 4. Previous period / year amounts have been regrouped/ reclassified to make them comparable with those of current period/year.

For and on behalf of the Board

Place: New Delhi
Date: November 14, 2018

Panacea Biotech Limited

Dr. Rajesh Jain
Managing Director

Regd. Office : Ambala-Chandigarh Highway, Lalru-140501, Punjab
CIN: L33117PB1984PLC022350 - Ph. No. 91-11-41679000, Fax: 91-11-41679070,
Website: <http://www.panacea-biotech.com>, E-mail: Corporate@panaceabiotech.com



HINDUSTAN TIN WORKS LIMITED

REGD OFFICE : 426, DLF TOWER A, JASOLA, NEW DELHI-110025

